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Abstract 
Brucellosis is one of the major endemic zoonotic diseases worldwide, and it has history 
dating back to 1937 in Iraq when it was first isolated by an Iraqi physician.  In order to establish 
a solution for the continuous devastating impacts of the disease in humans and livestock, the 
Brucellosis Control Program was established in 1995.  The main responsibilities of this program 
were setting and implementing the appropriate strategies for controlling the disease.  After the 
war in 2003, the United Nation organization for Food and Agriculture (FAO) developed a 
strategic plan to control the disease.  The main goal of the project was to improve productivity in 
the livestock sector and reduce the prevalence of disease in small ruminants (sheep and goats) to 
less than 2%, and less than 0.2% in cattle and buffalo.  Achieving such goals ultimately would 
reduce the disease incidence among the human population from more than 27.2 cases/100,000 
persons in 2002, to less than 4 cases/100,000 people within 15 years.  A serological surveillance 
was conducted and revealed the apparent prevalence of the disease in sheep and goats, cattle, 
buffalo, and camels was 6.51%, 1%, 1.48%, and 0.02%, respectively in Iraqi governorates except 
the three northern governorates of Kurdistan province .   Based on surveillance results, a 
vaccination policy was the only appropriate strategy that could be chosen to control the disease.   
Four vaccination campaigns were implemented in 2006, 2007, 2008, and 2009, with a total 
number of vaccinated animals each year at 10099972, 4698482, 753153, and 1833482 head, 
respectively.  The primary satisfactory outcome of the program was the apparent decline in 
livestock abortions leading to obvious increases in productivity.  Regarding the incidence of 
brucellosis among the human population, the apparent decline in the middle and south of Iraq 
began with the vaccination phase of the control program in 2006. The results represented a 
  
significant decrease in human cases after only four vaccination campaigns of a program that was 
intended to continue for 15 years. 
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CHAPTER 1 - Literature review 
Introduction  
Brucellosis,‎whic h‎is‎also‎known‎a s‎“U ndulant‎f ever”,‎“ Mediterranean‎fe ver”‎or‎“ Malta‎
fever” (WHO, 2006), is a major infectious disease afflicting humans and a wide range of 
domesticated animals and wildlife. (Robinson, 2003; Eschenbrenner et al., 2002; Laria et al., 
2006).  It is known to be a worldwide problem and one of the most important among zoonoses in 
the Mediterranean region, India, and Central and South America.  Although there has been 
continuous progress in controlling Brucellosis, it still remains a major health hazard and of great 
economic importance (Nicolas, 1998; Carrera et al., 2006).   
It is well known that the main sources of Brucellosis in humans are infected animals 
(sheep, goats, cattle and swine); and in the world, it has been reported there are approximately 
1.8 billion sheep and 50 countries with epidemic regions of B. melitensis; 1.3 billion cattle, and 
101countries with epidemic regions of B. abortus; and 0.9 billion swine, and 33 countries with 
the epidemic regions of B. suis (Deqiu et al., 2002).  
Etiology 
   The disease is caused by several species belonging to Brucella genus, which are aerobic, 
non-motile, Gram-negative, facultative intracellular coccobacilli.  The genus Brucella belongs to 
the alfa-2 subgroup of the class proteobacteria.   It is subdivided, on the basis of its pathogenicity 
and host preference into seven species B. abortus, B. melitensis, B. suis, B. canis, B. ovis, and 
B.neotomae (Robinson, 2003; Hoover et al., 1997; Eschenbrenner et al., 2002).   Recently, a new 
strain affecting marine mammals isolated and tentatively named (B. maris), was first described in 
1994 when a bacterial isolate from an aborted fetus of a bottlenose dolphin (Tursiops truncates) 
 2 
was characterized as a nontypical Brucella species (Forbes et al., 2000).   A recent proposal 
suggested division of B. maris into at least two species: B. pinnipediae for strains from pinnipeds 
(seals, sea lions, and walruses) and B. cetaceae for isolates from cetaceans (whales, porpoises, 
and dolphins) (Institute for International Cooperation in Animal Biologics. 2007).   B. abortus 
and B. suis have been isolated worldwide from a great variety of wildlife species, such as bison, 
elk, feral pigs, wild boar, European hares, foxes, African buffalo, eland, water buck, reindeer, 
and caribou, and regarding B. melitensis, although it is rarely reported in wildlife, cases were 
reported in Europe in chamois and ibex (Godfroid, 2002).  B. melitensis occurs most frequently 
in the general population and it is the most pathogenic and invasive species of Brucella, 
followed, in order, by B. suis and B. abortus (Community Health and Disease Surveillance 
Newsletter, 2002).  
 
Table  1.1: Different Brucella species, biovars, and hosts 
Species Biovar/ 
Serovar 
Natural host Human 
pathogen 
B. melitensis 1 – 3 Goat, Sheep Yes 
B. abortus 1 – 6, 9 Cattle Yes 
B. suis 1 , 3 Swine Yes 
 2 Hares Yes 
 4 Reindeer, Caribou Yes 
 5 Rodents Yes 
B. canis None Dogs, Other canids Yes 
B. ovis None Sheep No 
B. neotomae None Desert wood rat No 
B. maris  Marine mammals  
 
   All Brucella species are not host specific and may be transmitted among species under 
appropriate conditions (Robinson, 2003).  International scientific organizations have indicated B. 
melitensis is the most virulent species of all the Brucellae (OIE, 1996). 
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Transmission 
   Brucellosis still remains a major zoonosis and an important cause of travel–associated 
illness.  Humans can acquire the disease through consumption of infected, unpasteurized animal 
milk products (Laria et al., 2006; Carrera et al., 2006; Mendez et al., 2003; Institute for 
International Cooperation in Animal Biologics, 2005), and individuals who come in contact with 
infected farm animals or with animal-derived tissues are at risk.  In addition, inhalation of 
infected aerosolized particles including dust, soil and water has been reported (Laria et al., 2006; 
Fiori et al., 2000; Deqiu et al., 2002).   Transmission from human to human is very rare but has 
been documented after blood transfusion and bone marrow transplantation, and neonatal 
infection can be acquired transplacentally (Mosayebi et al., 2005) during delivery and postnatally 
by breast milk (Carrera et al., 2006; Lubani et al., 1988).  Transmission through sexual contact 
usually does not occur, with the exception of very rare cases (Bossi et al., 2004).   The disease 
remains among the most commonly recognized causes of laboratory-transmitted infection; 2% of 
all brucellosis cases are laboratory acquired (Mazuelos et al., 1994).   Accidental human 
inoculations may occur during vaccination of animals (Ashford et al., 2004).   The infection rate 
of laboratory-associated infections has ranged from 30% to 100% depending, among other 
factors, on the location of workers, if aerosol–generating procedures have been performed, and 
the concentration of microorganisms in contaminated media is high (Yagupsky and Baron, 
2005).  
    Initial infection in the reservoir animal species is often followed by abortion and 
subsequent delay or permanent infertility.  Infected animals shed organisms in uterine discharge 
following abortion and subsequent parturition and also in colostrum and milk (Robinson, 2003; 
WHO/OIE/FAO/CDC, 2006).   Disease is typically transmitted when susceptible animals come 
into direct contact with tissues or discharges from infected animals and as a result from the 
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ingestion of contaminated material.  Once the susceptible animal ingests the organism, the 
bacteria progress to regional lymph nodes where they reside during the incubation period, which 
may range from two weeks to over months.  After a subsequent brief phase when the bacteria are 
in the blood stream, the organism localizes in the uterus, placenta, udder, and/or regional lymph 
nodes (Alton et al., 1988).   Transmission via artificial insemination has been reported to occur 
with relative certainty (FAO, 2000).   Venereal infection can occur, but this is mainly seen with 
B. suis infection (Robinson, 2003).  Both B. abortus and B. melitensis can be transmitted from 
dams to calves, lambs, and kids, and a smaller proportion of lambs and kids can be infected in 
utero; however, the majority of infections are probably acquired by consumption of colostrum or 
milk (European Commission, 2001).   Bruella ovis is often transmitted among rams by passive 
venereal transmission via ewes that can carry this organism in the vagina for at least two months, 
acting as a mechanical vector. Contamination of pastures does not seem to be an important 
method of transmission for B. ovis (Institute for International Cooperation in Animal Biologics, 
2007).  Brucella has been found in lungworms (Parafilaroides sp) in harbor seals where the 
parasites may act as vectors.  Ingestion of infected seals has been suggested as a possible route of 
exposure for polar bears (Institute for International Cooperation in Animal Biologics. 2007).  
 
 
Brucella as Bioterrorism Agent 
 
  A bioterrorism attack is the deliberate use of viruses, bacteria or other germs (agents) to 
cause illness or death in people, animal, or plants.  These agents are typically found in nature, but 
it is possible they could be changed to increase their ability to cause disease, to make them 
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resistant to current medication, and to increase their ability to spread into the environment (CDC, 
2007).  The most likely form of deployment is by airborne release of the agent as an aerosol or 
powder preparation (White, 2002).  Bioterrorism agents can be separated into three categories 
(A, B, C) according to established criteria, and the common characteristics of each category are: 
A:  Easily spread or transmitted from person to person. 
- Result in high death rate. 
- Cause public panic. 
- Require special action for public health preparedness. 
B:  Moderately easy to spread. 
- Moderate illness rates and low death rates. 
- Require specific enhancements in CDC lab capacity. 
C:  Easily available. 
- Easily produce and spread. 
- Have potential for high morbidity and mortality rates. (CDC, 2007a; CDC, 2007b). 
 
Interest in Brucella species as a biological weapon stems from the fact that airborne 
transmission of the agent is possible, via entry through mucous membranes such as the 
conjunctiva, oropharynx and respiratory tract and skin abrasions. The infectious aerosol dose for 
humans is considered to be 10-100 organisms (Boosi et al., 2004).  Although the causative agents 
of brucellosis are categorized as incapacitating agents where infections caused by aerosols likely 
produce large numbers of casualties with little mortality, brucellosis deserves consideration by 
defense planners because of its extraordinary infectivity (Ciestlak et al., 2000).  Both B. 
melitensis and B. suis have been developed experimentally as biological weapons by state-
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sponsored programs, and their relative stability in aerosols, combined with low infectious doses, 
makes them suitable agents for this purpose (WHO/OIE/FAO/CDC, 2006). 
 
 Survival of Brucellae in the Environment  
 
Brucellae are sensitive to exposure to heat and most disinfectants but can survive in the 
environment for up to two years under specific conditions, becoming a continuous threat to both 
humans and animals (Boosi et al., 2004).  The ability of Brucellae to persist outside mammalian 
hosts is relatively high compared with most other non-sporing pathogenic bacteria, under 
suitable conditions.  Numerous studies have assessed the persistence of Brucella spp. under 
various environmental conditions.  When pH, temperature and light conditions are favorable, 
including high humidity, low temperature and absence of direct sunlight, Brucellae may retain 
infectivity for several months in water, aborted fetuses and fetal membranes, feces and liquid 
manure, wool, hay, and on buildings, equipment and clothes.  Brucellae are able to withstand 
drying, particularly in the presence of extraneous organic material and will remain viable in dust 
and soil.  Survival can be prolonged at low temperatures, especially below 00 C (European 
Commission, 2001).  In countries where traditional hand-made techniques are still used to 
manufacture dairy products like cheese and yogurt, non-pasteurized fermented dairy products 
cannot be considered Brucella-free after fermentation processes and subsequent storage, 
especially if the raw milk came from endemic areas (Estrada et al., 2005). Tables 1.2 and 1.3 
show the persistence time of B. melitensis and B. abortus in environmental settings. 
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Table  1.2: Studies on survival time in the environment (European Commission, 2001) 
 
 
  
Environment Conditions 
Survival time 
 
Direct sunlight < 31º C 4 h 30 m 
Water - 4º C 4 months 
Water (Laboratory) 20º C 2.5 months 
Water (Lake) 37º C. PH=7.2 < 24 hours 
8º C. PH=6.5 > 2 months 
Soil Dried in Laboratory < 4 days 
Dried at 18º C 69-72 days 
Wet < 7 days 
Humid atmosphere > 2 months 
Autumn (90% humidity) 48-73 days 
February(Rapid drying) 72 days 
Urine 37º C, PH=8.5 16 hours 
8º C, PH=6.5 6 days 
Raw milk 25-37º C 24 hours 
8º C 48 hours 
- 40º C 2.5 years 
Whey 17-24º C < 5 days 
5º C > 6 days 
Manure / dung Summer 24 hours 
25º C 1 month 
Winter 2 months 
8º C 12 months 
-3º C 3 months 
Manure / Liquid Summer 3 months 
Winter 6 months 
In tank 1.5 months 
In tank (12º C) > 8 months 
Wool Warehouse 4 months 
Hay - Several days – Month 
Street dust - 3 – 44 days 
Wooden walls or floors of pens - 4 months 
Pasture Sunlight < 5 days 
Shade > 6 days 
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Table  1.3: Studies on survival time in dairy products (European Commission, 2001) 
 
Product Species of Brucella Temperature (ºC) PH Survival time 
 Milk: B. abortus 71.7 - 5–15 seconds 
 B. abortus 38 4.00 < 9 hours 
 B. abortus 25 – 37 - 24 hours 
 B. abortus 0 - 18 months 
Cream: B. abortus 4 - 6 weeks 
 B. melitensis 4 - 4 weeks 
Ice cream: B. abortus 0 - 30 days 
Butter: B. abortus 8 - 142 days 
Cheese:     
Various B. abortus - - 6–57 days 
Various B. melitensis - - 15–100 days 
Feta B. melitensis - - 4 – 16 days 
Pecorino B. melitensis - - < 90 days 
Roquefort B. abortus & B. melitensis - - 20 – 60 days 
Camembert B. abortus - - < 21 days 
Erythrean B. melitensis - - 44 days 
Cheddar B. abortus - - 6 months 
White B. melitensis - - 1–8 weeks 
Whey: B. abortus 17 – 24 4.3 – 5.9 < 4 days 
 B. abortus 5 5.4 – 5.9 > days 
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Control Policies 
 
It is generally accepted that before a zoonoses control program can be designed and 
implemented, a well-functioning surveillance system that can be fed with valid data collected 
from the field must be established.  The main purpose of surveillance would be to determine the 
prevalence of disease so appropriate measures for control can be taken (European Commission, 
2001).  Over the years there have been a number of guidelines and manuals published on 
brucellosis, with particular emphasis on B. melitensis. Data from the Middle East and Eurasia 
where the disease is endemic indicate a positive correlation between the level of B. melitensis 
infections in small ruminants and the number of humans infected (FAO, 2009).  There are three 
main control strategies for controlling Brucellosis, each with its own advantages and 
disadvantages, Table 1.4 (Nicholas, 1998; European Commission, 2001). 
1) Mass vaccination:  
* Advantages: 
     - Lower cost 
     - Easy to manage 
     - Herd immunity quickly established 
 * Disadvantages: 
       - Abortions induced by vaccine post vaccination 
       - Difficulty to distinguish between Infected and vaccinated animals 
       -  There is some kind of public health hazards 
   2)   Vaccination of young animals and elimination of the infected ones. 
  * Advantages: 
        - Minimize abortions 
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        - Differentiation of infected from vaccinated 
  * Disadvantages: 
         - Herd immunity slowly established 
   3)   Elimination of infected animals: 
   * Advantages: 
         - Elimination of infected animals 
   * Disadvantages: 
         - Higher cost 
         - Requires appropriate legislation 
         - Need for efficient veterinary services (Nicholas, 1998; European Commission, 
2001). 
     There have been many controversies regarding the most appropriate policy that should 
be implemented to start control programs in any country intending to control the disease. The 
controversies generally surround the hazards from using the live vaccines due to the nature of the 
bacterial strain used in vaccine production. 
    International agencies such as WHO and FAO have suggested that national control 
programs should depend on a whole-flock vaccination scheme as a cost-effective strategy until 
disease prevalence has been reduced; only then would test-and-slaughter be implemented to 
eradicate the disease (Bardenstein et al., 2002; Carrera et al., 2006).   In the meantime, there has 
been opposition to such policy due to adverse effects encountered in the field and public concern 
of possible risks to the human population following secretion of the vaccine strain in milk. 
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Table  1.4: Summary of the advantages of Brucellosis control strategies 
Strategy. Advantages. Disadvantages. 
- Mass 
vaccination 
 
- Lower cost 
- Easy to manage 
- Herd immunity quickly 
established and 
maintained by 
vaccinating young 
animals 
- Well accepted by 
owners 
- Abortions post 
vaccination 
- Difficulty to distinguish 
between vaccinated and 
infected animals 
- Public health hazards. 
- Infected animals remain 
on farms along their 
economical ages 
 
- Vaccination of   
young animals 
and 
elimination of 
infected 
- Minimize vaccine 
induced abortions 
- Can differentiate 
between infected and 
vaccinated 
- Herd immunity slowly 
established 
- Difficult to manage 
- Elimination of 
infected 
animals 
 
- If successful, will lead 
to elimination of 
infected animals 
- Diagnostic tests are 
more accurate in non-
vaccinated animals but 
still not optimum 
 
- Cost is very high, and 
may require a whole 
herd slaughter to be 
effective 
- Requires an efficient and 
very well organized 
veterinary service 
- Suitable for low disease 
prevalence areas only 
- Risk of epidemics and 
subsequent human 
infection 
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 Brucella vaccines 
For most infectious diseases, vaccination of the entire animal population, repeated at 
regular intervals, is followed by a significant decrease in prevalence, and the first important issue 
is to choose the safest and the most appropriate vaccine (Blasco, 1997).  According to the 
devastating consequences of the socioeconomic and medical impacts of brucellosis, many studies 
and much effort have been implemented to control the disease in different ways, and vaccination 
attempts have been one of the those (Schurig, 2002).   There have been different kinds of 
vaccines used for controlling the disease in different species and many have been discarded 
because of the low level of immunity produced by them.  The effective classical vaccines are 
S19 in cattle and Rev 1 in small ruminants; however, vaccine-induced antibodies to the O-
polysaccharide of the lipopolysaccharide may be difficult to distinguish from those resulting 
from infection, complicating diagnosis (Moriyon et al., 2004).  The most successful vaccines 
hitherto have been those employing live attenuated derivatives of Brucella spp. (Schurig, 2002). 
 
Live Brucella Vaccines 
B. abortus S19 vaccine 
The S19 vaccine has been most widely used to prevent bovine brucellosis (Nicoletti, 
1990).  This strain was described in 1930 but had been isolated from a bovine milk sample in 
1923. The isolate was left at room temperature for more than a year and subsequently was found 
to be attenuated (Schurig, 2002).  It has smooth morphology and normally is unable to grow in 
the presence of erythritol (Jones et al., 1965; Beckett and Mc Darmaid, 1985).  The effectiveness 
of this vaccine depends on several factors, including the age of targeted animals, dose 
 13 
concentration, route of administration, and prevalence of the disease in infected herds (Arenas-
Gamboa et al., 2009).  Prevention of brucellosis in cattle can be achieved by vaccinating heifers 
with B. abortus strain 19 (S19), which induces production of antibodies to the O antigens of 
lipopolysaccharide (LPS) (Nicoletti, 1990).   Several studies have addressed a wide range of 
vaccine concentrations administered by different routes, and has been determined that the best 
protection  occurred via subcutaneous inoculation at a concentration of 11.5 x 1010 cfu/dose 
when used in heavily infected areas.  The subcutaneous route of inoculation is apparently 
superior to the conjunctival route (Fensterbank and Plommet, 1979).  In an earlier study, the 
recommended concentration was 6 x 1010 cfu/dose (Drimmelen and Steyn, 1958).  The immune 
responses from reduced doses of B. abortus (S19) vaccine have been studied by many 
researchers.  It was suggested that starting with a subcutaneous inoculation of 9 x 1010 cfu/dose 
followed by conjunctival inoculation at 5 x 109 cfu/dose six to eight months later would provide 
the best protection for heifers.  However, has been recognized that two vaccinations by the 
conjunctival route with 5 x 109 cfu/dose, would be simpler, more economical, as effective, and 
would have the advantage that vaccination could be done at any age without risk of serological 
response (Fensterbank and Plommet, 1976). 
B. abortus RB51 
Vaccines based on killed cells of virulent strains administered with adjuvant induced 
significant protection but also unacceptable levels of antibodies that interfered with diagnostic 
tests.   Development of the rifampicin-resistant mutant B. abortus, RB51 strain overcame the 
problem and provided safe, effective vaccination against bovine brucellosis and exhibited 
negligible interference with diagnostic serology (Schurig, 2002).  Strain RB51 (SRB51) of B. 
abortus is a laboratory-derived rough mutant of the standard virulent strain of B. abortus 
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(S2308).  This mutant lacks most of the LPS O-side-chain found in S19 and in naturally 
occurring field strains of virulent B. abortus, and the reduced O-side-chain prevents the 
bacterium from inducing antibody formation in vaccinated cattle (Schurig et al., 1991).   Using 
this vaccine during the eighth month of pregnancy at a concentration of 1 x 109 cfu/dose, did not 
induce abortion, but it was recovered from milk for up to 69 days post-vaccination (Uzal et al., 
2000).  The RB51 vaccine is not effective in sheep against B. melitensis infection, but it can be 
used in the replacement of B. abortus S 19 vaccine for preventing bovine brucellosis, increasing 
the efficiency of serologic identification, and removal of infected cattle from herds in the United 
States (Stevens et al., 1994; OIE, 2009). 
B. melitensis Rev-1 vaccine 
The B. melitensis Rev-1 vaccine is the most widely used vaccine for prevention of 
brucellosis in sheep and a goat, which is the reference vaccine by which any other vaccine 
should be, compared (OIE, 2009).  It is a live attenuated B. melitensis strain derived from a 
virulent B. melitensis isolate which became dependent on streptomycin for growth, (Elberg and 
Faunce, 1957).  Brucella melitensis Rev-1 vaccine is used as a freeze-dried suspension of live B. 
melitensis Rev-1 strain.  It is normally given to lambs and kids between three and six months of 
age as a single subcutaneous injection.  The standard dose is between 0.5 x 109 and 4.0 x 109 
viable organisms. The use of this vaccine administered by the conjunctival route with a 
minimum dose of 1-5 x 108 produced similar protection without a persistent antibody response 
(OIE, 2000).  Subcutaneous vaccination induces strong interference in serological tests and 
should not be recommended in eradication programs.   Because the vaccine produces similar 
protection without inducing persistent antibody responses when given by the conjunctival route, 
it can be used in eradication programs combined with vaccination (Martin et al., 1999).   The 
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application of the live B. melitensis Rev-1 vaccine in whole-flock vaccination programs is the 
only practical method of controlling B. melitensis infection in small ruminants in areas having 
high prevalence, extensive management systems and low socio-economic levels (Blasco, 1997). 
B. suis S2 vaccine 
An orally administered brucellosis vaccine, Brucella suis strain 2 vaccine was developed 
in China.  It is effective for oral vaccination of sheep, goats, cattle and pigs and has been widely 
used for prevention of animal brucellosis in China over the past 15 years, and about 30-40 
million doses of the vaccine are produced every year (Xina, 1986).  Vaccine strain S2 was found 
to be protective in different domestic animal species when inoculated orally, especially pigs 
exposed to wild B. suis through conjunctival mucous membranes.  The vaccine provided 75% 
protection when pigs were vaccinated twice two to three months apart.  However, protection was 
absent when vaccinated female animals were challenged by mating them with an infected boar 
excreting B. suis in semen (Nicoletti, 1990).  
Killed Brucella Vaccines  
B. abortus 45/20 
Strain 45 was first isolated in 1922 in Great Britain from a cow. It was a rough strain 
developed by 20 passages in guinea pigs.  The strain was shown to have good immunizing 
properties in guinea pigs and cattle.  Its ability to revert to the virulent smooth status was the 
reason for using it as an inactivated vaccine with adjuvant.  The main disadvantages of this 
vaccine were the marked local reaction at the injection site and the prolonged antibody 
interference in the serological tests (Bossi et al., 2004). 
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B. melitensis H38 
Brucella melitensis H 38 vaccine was a suspension of formalin-killed cells in incomplete 
adjuvant used at a concentration of 15 x 109 cells/ml.  This B. melitensis killed vaccine was 
effective against a B. abortus challenge (Renoux and Renoux, 1973).  However, the vaccine 
induced high, persistent titers and caused long lasting unacceptable local reactions at the site of 
injection (Nicoletti, 1990). 
 
Human Vaccines against Brucellosis 
B. abortus 19-BA vaccine 
The 19-BA vaccine is a derivative from B. abortus strain 19 where dissociated colonies 
were selected and cultured, called 19-BA by Vershilova to distinguish it from the original seed.  
The immunogenic dose of this strain was studied and determined by subcutaneous and cutaneous 
administration in guinea pigs.  Immunity was evaluated against virulent cultures of B. melitensis 
and B. suis, and the first test of this vaccine was carried out in human volunteers in 1946, who 
received 20-40 million organisms subcutaneously.  The studies were continued and later in 1947-
1952, a dried vaccine was made and used to vaccinate 5,000 workers at risk of infection.  It was 
determined that the immunogenic and safe vaccine dose for subcutaneous vaccination was to 
300-600 million organisms.  It was found that immunological reactivity was maintained for a 
long time (2-3 years) in the majority (56-63%) of persons working in endemic brucellosis areas 
or abattoirs.  Since that time, the epidemic control services in the former USSR used human 
vaccination as a main prophylactic measure (Drimmelen et al., 1958).  
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B. abortus 104M vaccine 
The 104M vaccine is one of several Brucella vaccines that have been used in China to 
prevent and control B. abortus infection in humans (Dequi et al., 2004).  
B. melitensis WR201 vaccine 
Rough Brucellae mutants have been sought as vaccine candidates because they do not 
induce seroconversion (Nikolich et al., 2010).  The live-attenuated, purine-auxotrophic mutant 
strain of B. melitensis, WR201 was tested for its ability to elicit cellular and humoral immune 
responses and to protect mice against intranasal challenge with B. melitensis 16M.   Mice 
inoculated intraperitoneally with WR201 made serum antibodies to lipopolysaccharide and non-
O-polysaccharide antigens, and splenocytes from immunized animals released interleukin-2 (IL-
2), gamma interferon, and IL-10 when cultured with Brucellae antigens, which led to protection 
from disseminated infection (Hoover et al., 1999). 
In another study, the clearance of orally administered strain WR201 from lungs, livers, 
and spleens by eight weeks after immunization and the ability of the organism to induce a 
protective response against intranasal challenge with strain 16M suggest that induction of purine 
auxotrophy in B. melitensis has promise as a strategy for development of a safe, convenient, and 
effective human vaccine (Izadjoo et al., 2004).  These studies suggest that WR201 should be 
further investigated as a vaccine to prevent human brucellosis. 
Brucella Subunit Vaccine 
The antigenic fractions extracted from Brucella have been utilized in association with a 
variety of adjuvants to achieve immunity.  Some of the preparations include whole killed cells, 
cell envelopes, outer membrane proteins, insoluble residues of hot sodium dodecyl sulfate (SDS) 
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extract of cell envelopes (PG), soluble SDS extracts, Brucella soluble antigens (BASA), 
periplasmic proteins and salt extractable proteins, chemically modified Brucella proteins, smooth 
and rough LPS, and recombinant Cu-Zn superoxide dismutase (SOD) (Schurig et al., 2002).   
 Studies that addressed the importance of outer membrane proteins of B. ovis revealed 
that the fraction enriched in outer membrane proteins and rough lipopolysaccharide by using the 
hot saline extract may represent a useful alternative to B. melitensis Rev-1 or B. abortus 45/20 as 
a vaccine against B. ovis (Cassataro et al., 2007; Blasco et al., 1993).  A genetic vaccine based on 
the Omp31 gene elicited a strong cellular immune response and the available data suggested  
Omp31-pcDNA31 was a good candidate for use in future studies of vaccination against 
brucellosis (Doosti et al., 2009).  Moreover, some promising studies showed that outer 
membrane proteins could be useful for differentiating B. melitensis infection from B. melitensis 
Rev-1 vaccinated sheep (Zygmunt et al., 1994).  Regarding recombinant vaccines, a bacterium 
closely related to Brucella species, Ochrobactrum anthropi, was used as a vaccine vector for the 
delivery of Brucella antigens to mice, leading to protective immunity against brucellosis (He et 
al., 2002). 
Recombinant B. abortus L7/L12 ribosomal protein fused to maltose-binding protein 
(MBP), identified as T-cell reactive,  provided protective immunity in mice against brucellosis 
when immunized with this protein (Oliveria et al, 1996). 
A vaccine based on an outer membrane complex from B. ovis, encapsulated in poly-
epsilon-caprolactone (PEC) microparticles was developed and tested in rams.  Homogeneous 
batches of microparticles were prepared by a new double-emulsion solvent evaporation method 
called "Total Recirculation One-Machine System" (TROMS).   The microparticles had a mean 
diameter of two microns and displayed antigen loading of about 13 microg HS per mg of 
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microparticles. Subcutaneous vaccination of rams with 800 microg HS (hot saline antigenic 
extract of B. ovis) in PEC microparticles induced an adequate serological response against B. 
ovis antigens and conferred similar protection against challenge with B. ovis to that induced by 
the live attenuated B. melitensis Rev 1 reference vaccine (Munoz et al., 2006). 
Routes of Administration 
A large number of studies have been conducted to determine the most accurate method 
and dose for administration of different vaccines including subcutaneous (SC), intradermal (ID), 
intracaudal (IC), conjunctival (C), oral, intravaginal, and intrauterine (Nicoletti, 1990).   
Regarding the administration of Brucella vaccines, the most current practical and commonly 
used methods are outlined below. 
Subcutaneous Route (SC)  
Regarding B. melitensis Rev-1 vaccine, it can be given in a volume of 1 ml in two 
different concentrations.  The first one is the full dose containing 1-4 x 109 cfu/dose, and the 
second is a reduced dose containing 1 x 104 – 1 x108 cfu/dose (Blasco, 1997).   It has been shown 
that the use of reduced dose Rev-1 vaccine (1 x 105 cfu/dose) protects goats vaccinated in 
endemic areas for at least five years after immunization.   Regarding B. abortus S19 vaccine in 
calves three to eight months old, it can be administered in full dose 60 x 109 cfu/dose, and for 
adult animals, it can be given as a reduced dose 5 x109 cfu/dose (Plommet, 1995).  
Conjunctival Route 
Currently the conjunctival route of vaccine administration is widely used because it 
overcomes the problematic issues of using the live attenuated vaccines (Rev-1 and S19) that can 
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cause prolonged serological interference and abortions post vaccination (Blasco, 1997; Zundel et 
al., 1992). 
Aerosol Route 
In Turkey, aerosol immunization of sheep against brucellosis was successfully performed 
in lambs and ewes via exposure to 300 ml of 20 x 109 cfu/ml aerosol B. melitensis Rev-1 vaccine 
for 20 minutes and then taken to the pasture (Uysal, 1995). 
Oral Route  
The oral route is mainly used for the administration of B. suis S2 vaccine which is usually 
given via drinking water in a dose of 25-50 x 109 cfu/head (Nicoletti, 1990).  
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Epidemiology of Brucellosis 
Global Scenario 
The infection occurs worldwide in both humans and animals, but is most common in the 
Mediterranean countries of Europe and Africa, the Middle East, India, Central Asia, and Central 
and South America, with the highest numbers of cases occurring in Mexico, Argentina, and Peru 
(Mikolon et al., 1998; Boosi et al., 2004; First International Conference on Emerging Zoonoses, 
1997).  The disease does not exist in countries where bovine brucellosis (B. abortus) has been 
eradicated, which is usually defined as the absence of any reported cases for at least five years. 
These countries include Australia, New Zealand, Canada, Cyprus, Denmark, the Netherlands, 
Finland, Norway, Sweden (except for sporadic incursions from the south) and the United 
Kingdom as mentioned in the OIE  report of 2002 (Robinson, 2003; European Commission, 
2001).  However, a study for assessment of the risks associated with animals moved from herds 
infected with brucellosis in Northern Ireland found that 3.1% of animals moved in the six-month 
period prior to disclosure of infection in the source herd and subsequently tested, were 
seropositive in their destination herds (Stringer et al., 2008).  Brucellosis is a disease of domestic 
animals and humans in Central America (CA), where bovine and swine brucellosis caused by 
Brucella abortus and Brucella suis respectively, have been identified in all CA countries, while 
ovine and caprine brucellosis caused by B. melitensis has been detected in Guatemala.  The 
prevalence of bovine brucellosis is estimated between four and eight percent, with higher 
prevalence in dairy herds (Moreno, 2002). 
     Brucella melitensis infection in sheep appears to occur endemically in the 
Mediterranean region, especially along its northern and eastern shores, stretching through 
Central Asia as far south as the Arabian Peninsula and as far as Mongolia.  The disease also 
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occurs in Africa and India (European Commission, 2001).   Sheep, goats and their products 
remain the main source of infection, but B. melitensis in cattle has emerged as an important 
problem in some southern European countries, Israel, Kuwait, and Saudi Arabia.  It has been 
shown that the same problem exists in some South America countries, like Brazil and Colombia 
where B. suis biovar 1 has become established in cattle (First International Conferences on 
Emerging Zoonoses, 1997). 
 
Middle East 
    Although human brucellosis is a notifiable disease in some countries of the Middle 
East, it is often unrecognized and unreported.   In many countries, the awareness of brucellosis 
by medical specialists is very weak and, in most of the cases, public health laboratories are not 
performing diagnostic tests.   Brucellosis cases very often remain unrecognized and are treated as 
other diseases.‎‎Th ey‎a re‎ often‎la beled‎ „Fever‎o f‎u nknown‎c auses‟.‎‎‎F or‎th ese‎r easons,‎t he‎a ctual‎
number of cases of brucellosis is unknown and is believed to be much more than the officially 
reported number of cases.   Eastern Mediterranean countries experienced an increase in the 
number of human brucellosis cases in 1982-1990, and in seven countries of the region (Iran, 
Jordan, Kuwait, Oman, Saudi Arabia and Syria) about 82,000 cases were reported in 1988 as 
compared to 2,871 in 1985 (Refai, 2003). 
In 1977 the incidence of brucellosis in Makah, Saudi Arabia was found to be 0.8% in 
goats, 0.5% in sheep, 2.8% in camels and 3.6% in cows.  In the Asir region, the incidence of 
brucellosis went up to 18.2% in goats, 12.3% in sheep, 22.6% in camels and 15.5% in cows by 
1987. The overall human infection rate was reported in the range of 1.6-2.6 %, including both 
genders and all ages (El-Eissa, 1999).  In another study evaluating milk samples from 120 
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seropositive milking camels, B. melitensis biovars 1, 2, and 3 were isolated from 41 camels 
(34%) (Radwan et al., 1995).  In 1998, brucellosis ranked as the No. 1 reportable communicable 
disease (22.5%) in Saudi Arabian National Guard communities.   Human brucellosis cases 
increased sharply (4.9 to 69.5/100,000) during the period 1985-1990. The highest rate 
(79.6/100,000) was recorded in 1988 (Memish and Mah, 2001). 
In the Republic of Yemen, the reported prevalence of brucellosis among non-native goats 
from Africa was 5.6% and among non-native sheep from Africa was 1.7%.   The seroprevalence 
of human brucellosis ranged from 0% to 0.8% (Al-Shamahy, 1999).   
In the Kingdom of Jordan, according to a combined cross-sectional and longitudinal 
design to estimate seroprevalence of Brucella antibodies in sheep, the seroprevalence of 
brucellosis at the individual-animal level was 14.3% by RBT, 7.2% by ELISA, and 2.2% using 
both tests in series.   Moreover, the overall incidence of abortion was 20% and the specific 
incidence due to brucellosis was 13% (Al-Talafhah et al., 2003).   In camels, the incidence of 
brucella-specific abortion was investigated in 7 camel herds located in different locations in 
southern Jordan, the true prevalence of Brucella-seropositive was 12.1%, and thirteen (35.1%) 
herds had at least one positive camel (Al-Majali et al., 2008). 
Studies performed in different regions of Turkey showed that B. melitensis was 
responsible for approximately 14-31% of the abortion cases in sheep (Fatma and Zabit, 2008).  
In a study during the period 2004-2006, cattle sera analyzed were 32.92% and 34.64% positive 
by RBPT and SAT, respectively.  Farmer sera were positive at rates of 13%, 14.22% and 17.88% 
by RBPT, SAT and ELISA, respectively.  There was no significant gender difference for 
Brucella seropositivity.   Of the 28 sera from veterinarians, 13 (46.42%) were positive by the 
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three serological tests.   Moreover, a significant feature in patients with epididymoorchitis was a 
9.1% seropositive rate for brucellosis (Yetkin et al., 2005; Otlu et al., 2008). 
In Kuwait, a single serum sample was collected from each of 1,836 patients of different 
nationalities from January 2000 to December 2001.   A total of 455 serum samples (24.8%) 
having a titer of 1:160 were presumptively diagnosed as cases of brucellosis.   The peak for 
positive isolation was during April and May when Brucella spp were isolated from 123 blood 
cultures (74.1%).  The blood culture isolation rate was significantly higher in patients with a titer 
of 1:1,280 than in those with a titer of 1:160 (p < 0.05).  The study revealed that Kuwaiti and 
Bangladeshi nationals were most affected.   Significant titers on the STA test were detected in 
24.8% of the serum samples (Za et al., 1999). 
In Iran, a descriptive, cross-sectional study was conducted in north Khuzestan, southern 
Iran from March 2004 to June 2004.   A total of 3,594 persons took part in this study by 
randomized cluster sampling.  Two hundred twenty-eight out of 3,594 were positive for 
brucellosis (6.3%).  The study showed the prevalence of brucellosis among nomads in Iran 
washigh due to their life style (Alavi et al., 2007).  In the town of Baft, located in southeast Iran, 
home for about 1,350 camels, a study was done to investigate brucellosis in camels.  Serological 
examinations including the Rose Bengal Plate Test (RBPT), MRT and 2ME were performed on 
1,123 camel serum samples; positive results were obtained in 118 (10.5%), 96 (8.54%) and 89 
(7.92%) camels thus tested, respectively.   In another study aimed to determine the 
seroprevalence of B. canis, 102 blood samples from companion dogs were divided into two age 
groups (1-5 years) and > 5 years.  The overall prevalence was 4.90% (5 of 102), and the 
prevalence in dogs > 5 years was 9.3% (4 of 43), in comparison with dogs < 5 years 1.69% (1 of 
59) (Mosallanejad et al., 2009).   By using the GIS in explaining spatial distribution of 
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brucellosis in an endemic district in Iran, which was Bardsir district in the Kerman province 
located nearly to the central part of Iran, the annual incidence of human brucellosis was shown to 
be 141.6 per 100,000 inhabitants, and most of the high risk villages were seen in the north and 
south of that district (Haghdoost et al., 2007). 
In Israel, B. abortus was eradicated from cattle in the 1980s, using vaccination of female 
calves with strain 19 vaccine and implementation of a test-and-slaughter program. Young (two to 
six months old) female calf vaccination continues to be mandatory.   In 1988, B.melitensis 
emerged as a national problem and a test-and-slaughter program combined with Rev-1 
vaccination by the ocular route in young animals was conducted from 1993-97.  Over 40,000 
sheep and goats were culled before the program ceased due to budgetary constraints. However, 
the program resulted in a significant reduction in the incidence of human brucellosis (FAO, 
2009). 
Iraq 
Iraq is in both the northern and eastern hemispheres.  It is positioned in the Middle East, a 
recognized geographical region of southwestern Asia.  The country is boarded by the Arabian 
Gulf, and the countries of Kuwait, Saudi Arabia, Jordan, Syria, Turkey, and Iran.  Its land area is 
432,162 sq km (166,859 sq miles), and consists of 18 governorates, including Anbar, Basra, 
Muthana, Qadisiyah, Najaf, Arbil, Sulaymaniah, Kirkuk, Babil, Baghdad, Dahuk, Thiqar, 
Deyala, Kerbala, Missan, Ninava, Salahadin, and Wasit.  
Veterinary services in Iraq is controlled and supervised by the State Company for Veterinary 
Services (SCVS) in Baghdad since being established in 1924.  After 1990, the three northern 
governorates of Arbil, Dahuk, and Sulaymaniah, (the Kurdistan region), had their own 
administration.  The veterinary activities in the other 15 governorates are administered by the 
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State Company for Veterinary Services (SCVS) in Baghdad.  In general, there is a central 
veterinary hospital in each governorate that controls the work of several related veterinary 
dispensaries.  Accordingly, there are 18 central veterinary hospitals and 273 related dispensaries, 
including three central hospitals and 45 veterinary dispensaries in the Kurdistan region (Fig. 1.1). 
 
Figure  1.1: The Eighteen Governorates of Iraq 
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 Brucellosis has been considered one of the most endemic diseases in Iraq since 1937 (Al-
Zahawi, 1938).  A review of serological investigations of brucellosis among farm animals and 
humans in northern governorates of Iraq for the period 1974 – 2004 showed there were several 
attempts to determine disease incidence.  Paul Nicoletti (1986) reported 10.8%, 4.4%, 3.1% and 
1% positive results of samples obtained from human, goat, cattle and sheep, respectively.   In 
1999, Shareef et al, investigated the prevalence of brucella agglutinins in animals and man in the 
Qaradagh district, south of Sulaymaniah city and the results showed the percentages of positive 
goat and sheep by the card test were 3.36% and 1.34%, respectively.  According to the annual 
report of health directorate in Sulaymaniah, Iraq, the positive human sera showed 35% for males 
and 65% for females, with a male: female ratio of 1 : 1.8, and positive children sera (age range 
6–12 years) were only 4.2% of the total positive human sera (Shareef, 2006).  In a study of the 
occurrence and epidemiology of Brucella spp in raw milk samples in the Basra province, it was 
shown that 24.2% of 420 milk samples collected were seropositive by the milk ring test, and the 
overall prevalence of Brucella in milk produced in the Basra province of Iraq was 14.7% by 
culture isolation results (Abbas and Al-dewan, 2009).  It was shown that the prevalence of 
brucellosis was higher in the suburban semirural area (29.3%) than the rural and urban areas of 
the Basra region (Yacoub et al., 2006).   
According to the personal communications, official data of the Iraqi Ministry of Health 
(MOH) in Baghdad regarding the annual human infected cases indicated the disease was at 
minimum levels during the late 1980s.  However, the disease incidence among humans began a 
serious increase during 1990-1995, most likely due to the economical sanction of United Nation 
resolutions that caused a huge shortage in medical capabilities.  The situation improved due to 
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the Oil for Food and Medicine agreement between Iraq and the United Nation in 1996. Table 1.5 
and Figure 1.2. show the seasonality of disease, and the data demonstrates an increase in human 
cases during the season of parturition which is the same season when abortions increase as 
shown in Table 1.6 and Figure 1.3. 
 
 
Table  1.5: Human infected cases in Iraq for the period 1988-2003 
 
Year Cases  Year Cases 
1988 1892 1996 7531 
1989 2464 1997 8911 
1990 2819 1998 5305 
1991 13106 1999 7297 
1992 14546 2000 8030 
1993 14989 2001 8166 
1994 15476 2002 7189 
1995 19040 2003 No Data * 
 
( * ) In 2003, the data was not accurate because of the war and the total collapse in all the 
official governmental foundations in middle and south of Iraq.  
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Figure  1.2: The human infected cases in Iraq for the period 1988-2003 
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Table  1.6: Monthly recorded human brucellosis cases in Iraq for the period  
1999-2002 
 
Month 1999 2000 2001 2002 
January 272 397 486 286 
February 404 501 489 401 
March 567 463 451 517 
April 658 969 968 703 
May 972 788 814 689 
June 835 892 1006 909 
July 850 869 891 855 
August 661 1069 837 811 
September 564 750 801 654 
October 629 443 642 510 
November 652 346 434 437 
December 423 444 347 417 
Total 7287 7958 8166 7189 
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Figure  1.3: Seasonality of Human Cases for the Period 1999-2002 
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It is important to mention that socio-political issues have had significant influence on 
administrative and governmental structures.  After the second Gulf war in 1991, there were 
several administrative changes in Iraq.  The three northern governorates (Arbil, Duhuk, and 
Sulaymaniah) established their own administration which covered what recently has been known 
as the Kurdistan province, representing about 13% of the Iraq population.  Accordingly, it was 
crucial to handle the data inputs as if there were two different veterinary administrations.  The 
first one is in Baghdad which controls the veterinary activities in 15 governorates, and the second 
one is in Erbil where it controls the veterinary activities in the Kurdistan province.  The second 
administration implemented vaccination 1998-2005 by using the Rev-1 vaccine administered via 
the conjunctiva route.  The targeted animals were lambs and kids of three to eight months age, 
and the total vaccinated animals were 4,935,313 heads during that period. 
There were significant differences between the control strategies of the two administrations, 
which could not be evaluated by the same parameters.  Accordingly, it was more accurate to 
calculate the incidence of each region separately based upon the data shown below in table 1.7. 
During the period between 2001 and 2009, and according to the reported human infected 
cases in health administration in both Baghdad and Erbil, it was determined that there was 
significant difference in incidence between the two regions.  Infected cases and disease incidence 
in the middle and south of Iraq are shown in table 1.10 and figure 1.6.  Regarding the Kurdistan 
province, infected cases and incidence are as shown in table 1.8 and 1.9, and figures 1.4 and 1.5. 
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 Table  1.7: Population of Iraq divided into two categories between 1988-2009. 
 
Year 
Iraq 
population 
Middle & South  
population 
Kurdistan 
population 
1988 17,814,801 15,498,877 2,315,924 
1989 18,349,311 15,963,901 2,385,410 
1990 18,899,860 16,442,879 2,456,981 
1991 19,409,189 16,885,995 2,523,194 
1992 19,932,244 17,341,053 2,591,191 
1993 20,469,395 17,808,374 2,661,021 
1994 21,021,022 18,288,290 2,732,732 
1995 21,587,514 18,781,138 2,806,376 
1996 22,249,812 19,357,337 2,892,475 
1997 22,932,429 19,951,214 2,981,215 
1998 23,635,988 20,563,310 3,072,678 
1999 24,361,133 21,194,186 3,166,947 
2000 25,108,525 21,844,417 3,264,108 
2001 25,748,669 22,401,343 3,347,326 
2002 26,405,133 22,972,466 3,432,667 
2003 27,078,334 23,558,151 3,520,183 
2004 27,768,699 24,158,769 3,609,930 
2005 28,476,664 24,774,698 3,701,966 
2006 29,202,819 25,406,453 3,796,366 
2007 29,947,491 26,054,318 3,893,173 
2008 30,711,152 26,718,703 3,992,449 
2009 31,501,397 27,406,216 4,095,181 
 
( * ) According to the United Nation records, Kurdistan province population represents 
13% of total Iraq population. 
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Table  1.8: Incidence of Brucellosis in Middle-South of Iraq 2001-2009 
 
 
Year 
 
 
Population 
of Middle and South 
  
Human infected 
cases 
 
Incidence/100000 
People 
 
2001 22401343 8166 36.45 
2002 22972466 7189 31.29 
2003 23558151 0 0 
2004 24158769 4993 20.66 
2005 24774698 5408 21.82 
2006 25406453 4234 16.66 
2007 26054318 3504 13.44 
2008 26718703 4417 16.53 
2009 27406216 4659 16.99 
 
( * ) In 2003, the data was not accurate because of the war and the total collapse in all the 
official governmental foundations in middle and south of Iraq.  
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              Figure  1.4: The Incidence of Brucellosis in the Middle-South of Iraq 2001-2009 
 
( * ) In 2003, the data was not accurate because of the war and the total collapse in all the 
official governmental foundations in middle and south of Iraq.  
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    Table  1.9: Human Brucellosis Cases in Kurdistan Province 2001-2009 
 
Year Erbil Duhuk Sulaymania Total 
2001 3069 2998 1538 7605 
2002 4040 1147 3425 8612 
2003 2059 624 2643 5326 
2004 900 1113 312 2325 
2005 638 499 359 1496 
2006 673 401 363 1437 
2007 1421 322 857 2600 
2008 1111 424 905 2440 
2009 772 295 1077 2144 
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Table  1.10: Incidence of Brucellosis in Kurdistan Province 2001-2009 
 
 
Year 
 
Kurdistan 
 population 
Human infected 
Cases 
Incidence/100000 
people 
2001 3,347,326 7605 227.19 
2002 3,432,667 8612 250.88 
2003 3,520,183 5326 151.29 
2004 3,609,930 2325   64.40 
2005 3,701,966 1496   40.41 
2006 3,796,366 1437   37.85 
2007 3,893,173 2600   66.78 
2008 3,992,449 2440    61.11 
2009 4,095,181 2144    52.35 
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       Figure  1.5: Incidence of Brucellosis in Kurdistan Province 2001-2009 
 
( * ) According to the stable and safety conditions during the war in 2003,  the records can be 
consider more accurate than that in middle and south of Iraq. 
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CHAPTER 2 - Serosurveillance Phase 
National Project for Controlling Brucellosis and Tuberculosis 
   The State Company for Veterinary Services (SCVS) established the National Project 
for Controlling Brucellosis and Tuberculosis (NPCBT) in 1995 due to the endemic status of 
brucellosis and the severe environmental and economic impacts at both human and livestock 
levels. The objectives of this project were the following: 
- Planning, implementing and supervising epidemiological surveillances. 
- Producing protective vaccines against the disease. 
- Producing diagnostic kits used for detection of the disease. 
   The official opening of the project was in July 1995 with limited resources due to the 
sanctions of the United Nation Resolutions against the ruling regime at that time. The project 
consisted of four main units: 
- Brucella diagnostic kits production unit 
- Brucella vaccines production unit 
- Tuberculosis unit 
- Laboratory animal unit 
   The work started with experimental trials for vaccines production such as Rev-1 
vaccine which provides protection against B. melitensis infection, and S19 vaccine which 
provides protection against B. abortus as shown in Table 2.1. Also, there was production of 
diagnostic kits used in laboratory for detection of the disease such as Rose Bengal Test antigen 
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(RBT), Serum Agglutination Test antigen (SAT) and Milk Ring Test antigen (MRT) as shown in 
Table 2.2.  
 
Table  2.1: Production Quantities of Rev-1 Vaccine 
 
Year Rev-1 
1999 53,000 
2000 1,582,700 
2001 230,200 
2002 262,000 
3/2003 30,000 
Total 2,156,700 
 
* More than 20,000 doses of S19 vaccine was produced according to the requests of the major 
dairy cattle stations when they intended to vaccinate only the remaining heifers (3–8) months of 
age. 
 
Table  2.2: Production Quantities of Diagnostic Kits (tests)  
 
Year RBT SAT          MRT 
1999 34156 1400 - 
2000 10824 1750 5700 
2001 20900 3700 1500 
2002 11616 2600 1200 
3/2003 3300 1150 - 
Total 70,796            10,600 8,400 
  
    After the war in 2003, there was total devastation and collapse in veterinary activities, 
including the NPCBT.  Accordingly, there was great need for restoration and rehabilitation of the 
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veterinary services in Iraq.  A series of meetings were held with FAO experts for this objective. 
The United Nations Development Group (UNDG) Trust Fund project (OSRO/IRQ/406/UDG) 
was initiated for the restoration of essential and urgent veterinary services in Iraq and a national 
plan was developed for control and surveillance of animal brucellosis. 
   One of the most important agreements was consideration of the Brucellosis Controlling 
Program as a module for controlling other zoonotic diseases in Iraq; therefore, a major 
surveillance was implemented to monitor the prevalence of diseases in different animal species 
(sheep, goats, cattle, buffalo and camels).  
Objectives of the Control Program 
 
The objectives of the control program were to improve productivity of livestock by 
conducting the following steps:  
1) Determine the seroprevalence and geographical distribution of Brucella infections in 
sheep, goats, cattle and buffalo by conducting a national serological survey. 
2) Design and develop a national brucellosis control program based on the results of the 
national survey. 
3) Employ strategic and active surveillance to monitor changes in prevalence of the 
disease in livestock with progress in reaching goals and allow management decisions 
to be made based on scientific judgment of surveillance data. 
4) Determine the main abortion causes in small ruminants.  
5) Enhancement of an attitude of team work between veterinary services and public 
health authorities regarding the continuous monitoring of the disease incidence in 
humans.   
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The main ultimate goal of the project was to improve the productivity in the livestock 
sector and reduce the prevalence of the disease in sheep and goats to less than 2% and less than 
0.2% in cattle and buffalo.  Ultimately, achieving the goals would reduce the disease incidence 
among human population from more than 27.5 cases/100,000 persons to less than 4 
cases/100,000 persons within 15 years. 
Serosurveillance Design 
 
    A cross-sectional study was performed to investigate some epidemiological aspects 
related to brucellosis status in different livestock populations in Iraq (sheep, goats, cattle, buffalo 
and camels). The serological survey was conducted to estimate the prevalence of brucellosis in 
susceptible animals and to establish the baseline for disease control strategies and options. The 
serosurveillance included the following topics: 
1) Sampling: 
Blood samples collection designed according to the population of each animal 
species in each governorate and based on updated records of livestock held by each 
owner. The sample size collected for each species was: 
- Shoats = 1020 blood samples, from 18 villages in each of 18 included governorates. 
- Cattle = 480 blood samples, from 8 villages in each of 18 included governorates. 
- Buffalo = 480 blood samples, from 8 villages in each 11 included governorates. 
- Camels = 480 blood samples, from 8 villages in a single included governorate.          
2) Questionnaire preparation: 
    A questionnaire was designed, pre-tested and administered to collect information about 
target animal herd health and management, considering all the required details needed to be 
 43 
collected from randomly selected livestock holders of each species under investigation.  
The questionnaire was designed in co-operation with FAO experts during a series of 
workshops held in Amman, Jordan. 
3) Database creation: 
All information and data collected by the prepared questionnaire were organized 
in access files.   
4) Field work: 
-  Blood sample collection 
       Survey field work has been completed with blood sample collected from the 
targeted species from different governorates.  The total blood samples collected from shoats, 
cattle, buffalo, and camels were 18,360, 8,640, 5,280, and 480 samples, respectively. 
Samples collected from the four mentioned species totaled 32,760. 
-  Questionnaire completion. 
5) Laboratory work: 
All blood samples were tested using the Rose Bengal Test (RBT), and this phase of 
the work was accomplished in the central veterinary hospitals in each governorate, and then 
all seropositive samples were confirmed by indirect ELISA testing at the NPCBT in 
Baghdad. 
6) Interactive map system creation: 
The true disease distribution status was able to be illustrated by using the Arc View 
software after entering the field information collected by the questionnaire and the laboratory 
results carried out by testing the blood samples collected.   
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Results of Surveillance 
 The results showed the apparent prevalence of disease in sheep and goats, cattle, 
buffalo, and camels was 6.51%, 1%, 1.48%, and 0.02%, respectively. In addition, the distribution 
of disease among the three main animal populations (sheep and goats, cattle, and buffalo) in 
different Iraqi governorates, except Kurdistan Province in the three northern governorates, was 
determined in the Figures 2.1, 2.2, 2.3, 2.4, 2.5, and 2.6. 
 
Table  2.3: Apparent Prevalence of Brucellosis Surveillance  
 
Governorate Shoats Cattle Buffalo Camel 
Ninava 4.90% 0.37% 0.56% - 
Kirkuk 16.37% 2.59% - - 
Baghdad 6.85% 0.69% 2.78% - 
Deyala 9.81% 0.56% 1.30% - 
Wasit 7.93% 0.74% 1.67% - 
Babil 4.59% 0.37% 0.02% - 
Kerbala 8.82% 0.93% 0.74% - 
Missan 3.23% 0.74% 0.37% - 
Thiqar 0.89% 0.02% 0.37% - 
Qadiseya 7.54% 1.11% 2.78% - 
Najaf 5.22% 3.70% 0.18% - 
Muthana 0.20% 0.02% - 0.02% 
Basra 1.67% 0.93% 5.35% - 
Anbar 7.78% 0.74% - - 
Salahadin 11.86% 1.48% - - 
Mean 6.51% 1% 1.48% 0.02% 
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Figure  2.1: Apparent Prevalence of Brucellosis in Sheep and Goats 
 
 
 
 
  
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
18.0%
 46 
 
 
 
 
 
 
 
Figure  2.2: Map of Apparent Prevalence of Brucellosis in Sheep and Goats 
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Figure  2.3: Apparent Prevalence of Brucellosis in Cattle 
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Figure  2.4: Map of Apparent Prevalence of Brucellosis in Cattle 
 
 
 
 
 
 
 
  
Brucellosis Prevalence in Cattle
(ELISA Test)
 49 
 
 
 
 
 
 
Figure  2.5: Apparent Prevalence of Brucellosis in Buffalo 
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Figure  2.6: Map of Apparent Prevalence of Brucellosis in Buffalo 
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CHAPTER 3 - Vaccination Phase 
The results of serosurveillance indicated sheep and goats were the main source of 
infection, and there was a decision to implement mass vaccination for controlling the disease by 
using Rev-1 and S19 vaccines: 
1) Rev-1 Vaccine 
Target animals:  sheep and goats. 
Route of administration: subcutaneous injection.  
Concentration: Full dose of 1x109/dose for young animals 3–8 months of age. 
             Reduced dose of 1x107/dose for adult animals. 
2) S19 Vaccine 
Target animals: cattle and buffalo female calves 3-9 months of age. 
Route of administration: subcutaneous injection. 
Concentration: Full dose 50 x 109/dose. 
Pilot Vaccination Campaign 
  Since the decision was to implement the mass vaccination policy in the first year of 
controlling the disease, there was significant need for SCVS to conduct a pilot vaccination 
campaign to evaluate capabilities and to determine strengths and weaknesses before starting the 
main mass vaccination campaign at the national level.  
The vaccine quantity available was 2,000,000 doses of Rev-1 vaccine provided by the 
Direct Aid Iraq agency (DAI), after endorsing the proposal of the Royal Netherlands Army for 
controlling cattle and small ruminants brucellosis in the Muthana governorate.  Both SCVS and 
DAI agreed on the following points: 
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1) Implement the project in five southern governorates instead of one, including 
Muthana, Basra, Qadiseya, Missan and Thiqar. 
2) The target animals were lambs and kids three to eight months of age, to prevent the 
risk of abortion that might occur due to the vaccine in adult pregnant females during the 
implementation. 
3) In order to distinguish between vaccinated and infected animals, the SCVS 
implemented tattooing for identification of vaccinated lambs and kids to avoid revaccinating 
them during the mass vaccination campaign within the coming few months in 2006. 
4) The DAI agency provided SCVS with 1,000,000 doses of Rev-1 vaccine and the 
remainder was kept in cold storage in the Erbil governorate of the Kurdistan region.  The vaccine 
was considered to be part of the national bulk of vaccine which was supposed to be received 
from the FAO as scheduled during the series of meetings in Amman, Jordan.   
5) Release the vaccine for use after conducting the quality control process in the 
laboratories of SCVS in Baghdad. 
6) Provide temporary work opportunity for 300 unemployed graduated veterinarians to 
work under the supervision of the governmental veterinary services during the vaccination 
campaign. 
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Figure  3.1: Coverage Area of the Pilot Vaccination Campaign in 
Southern Governorates 
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Vaccine Specification: 
- Manufacturer          :CZV   
- Origin                       : Spain 
- Kind of vaccine        : Rev-1 vaccine for subcutaneous administration 
- Concentration           : 1-2 x 109 /ml 
- Quantity                    : 2,000,000 doses 
- Presentation              : 25-dose glass vials with diluent 
 
Preparedness: 
Before starting the campaign, a meeting was held with directors of the central veterinary 
hospitals.  The meeting was at the veterinary hospital in the Muthana governorate, which was 
considered to be the headquarters of the campaign because of its very good organization.  All 
technical and logistic issues of the work were presented and discussed in the presence of the DAI 
agency representative.  The estimated number of the target animals in Muthana, Thiqar, Missan, 
Qadiseya and Basra governorates were 225,000, 75,000, 100,000, 75,000, and 50,000 head, 
respectively.  A total of 97 field vaccination teams were deployed as follows: 26 (Muthana), 20 
(Thiqar), 20 (Missan), 20 (Qadiseya) and 11 (Basra).   Although one of the aims of organizing 
this campaign was to provide the work opportunities to unemployed veterinarians, all personnel 
agreed the work should be conducted under supervision of the SCVS staff located in the 
governorates and with the work supervised by the SCVS headquarters in Baghdad.  Since, the 
 55 
campaign was fully supported by the DAI agency, all technical and logistic issues were 
discussed with the agency representative. 
 
Achievements: 
1) The four governorates started the campaign within the first week of December 2005, 
while the Qadiseya governorate started December 18th, 2005. All teams accomplished 
their mission within the 4th week of February 2006, except the Basra governorate which 
was accomplished on January 27, 2006. 
2) The total animals vaccinated (3-8 months of age) were 571,950 head distributed in 
Muthana with 245,543 head, Thiqar with 85,785 head, Missan with 9, 7000 head, 
Qadiseya with110, 000 head, and Basra with 33,522 head. 
3) The unused quantity of vaccine was 370,000 doses out off the 1,000,000 doses received 
from DAI, which was stored at the same veterinary hospital in Muthana.  The other 
1,000,000 doses were kept in cold storage in Erbil. 
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Table  3.1: Achievements of the Pilot Vaccination Campaign in Southern Governorates 
 
Governorate Population 
Sheep & Goats 
Estimated 
Target Animals 
Vaccinated 
Animals 
Muthana 1,925,000 225,000 245,543 
Basra 94,000 50,000 33,522 
Qadiseya 599,500 75,000 110,000 
Thikar 735,750 75,000 85,785 
Missan 726,100 100,000 97,000 
Total 4,080,350 525,000 571,950 
 
 
Obstacles 
    The SCVS was expecting delivery of required vaccine quantities and other 
requirements from FAO as scheduled for the full vaccination campaign.  In addition, the national 
veterinary staff was prepared for the first brucellosis mass vaccination campaign since the 
veterinary services was established in 1924.  The FAO informed SCVS there were financial 
problems in securing the required funds for the project (OSR0/IRQ/406/UDG,) Restoration and 
Development of Veterinary Services in Iraq, so it was impossible to obtain the necessary vaccine 
and thus had no chance of implementing the campaign.  Although there were several attempts to 
secure the vaccine, shortage of time and some governmental political issues did not allow 
resolution of the problem by the Ministry of Agriculture (MOA).    
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Alternative Plan 
    There appeared to be only one option to overcome the frustrating situation.  The 
NPCBT suggested an alternative urgent plan based on using the 370,000 doses of Rev-1 vaccine 
remaining from the pilot campaign implemented in the south.  The NPCBT had conducted 
several studies since 1997 on the locally produced Rev-1 vaccine administered by different 
routes and in different concentrations.   It was determined that 1 x 107 cfu/dose, when 
administered subcutaneously and timed well (between 1st of May and 1st of July), could produce 
protective immune responses without causing substantial abortion post vaccination.  Since the 
available vaccine concentration was 2 x 109 cfu/dose, dilution to a concentration of 2 x 107 
cfu/dose would increase vaccine doses 100 times and allow the final amount to be more than 
enough to cover the entire targeted population of approximately 12.5 million head.  The reason 
for choosing the above-mentioned time period was based on two factors.  The first one was the 
well-known fact that abortion occurred 40-60 days post vaccination, and the second factor was 
the season of parturition for ewes in Iraq.  There are two parturition seasons in Iraq, with the first 
(main) one is between March and May and the second season is between October and December 
each year.  Since, the pregnancy period of ewes is five months and the vast majority of them are 
delivered during April; the remaining pregnant ewes would be in the last month of pregnancy on 
May 1st.  If pregnant ewes were inoculated with the vaccine during this stage of gestation, they 
would not be at high risk of abortion.  The plan was fully discussed in SCVS headquarters, 
considering the critical security conditions in the central governorates of Iraq and all the required 
logistic requirements.  The final decision was to endorse the plan implementation in 13 out of 15 
governorates.  Implementation would not occur in Anbar and Saladin because of critical security 
conditions in these two governorates. 
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Preparedness  
   A general conference was held with the directors and deputies of the governorates 
central veterinary hospitals to discuss the campaign-related issues as follows: 
1) The number of required vaccination and supporting teams in each governorate 
included a total of 296 teams divided into 267 field vaccination teams and 29 supporting teams. 
2) The total number of working staff of 1,047 was divided into: 788 veterinarians, 243 
veterinary assistants and 16 follow-up personnel.     
3)  Endorse and release the required budget allocations of each governorate, regarding 
logistic needs, transportation of 267 field teams, and cold chain requirements that were needed to 
maintain the vaccine.   
4)  Because of shortage in the diluent quantities of Normal Saline 100 ml, the substitution 
was to use Normal Saline 500 ml used in human fluid therapy for diluting the vaccine in the field 
just before starting flock vaccinations. 
5)  There were problems regarding identification of vaccinated animals because of the 
inability to use tagging or tattooing methods. Tagging and tattooing supplies and instruments 
were not available and there was a high risk of screw worm infestation following both of these 
methods. To resolve this problem, NPCBT designed and prepared a card identity of veterinary 
services which was offered to the livestock owners by field vaccination teams. All details of 
veterinary activities were listed on the card identity, and the information on the card was 
organized in records and software by the epidemiological units in central veterinary hospitals in 
the 15 governorates which were done according to the coding system established by the SCVS. 
7)  Appendix A shows the procedure for diluting the vaccine from the concentration of 
1x109/dose to the concentration of 1x107/dose used by the field vaccination teams. 
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Achievements 
Coverage Percentage 
   Total vaccinated animals in covered governorates included 9,528,022 head of the 
estimated 12,693,391 head. The coverage rate was 75.06%, and when the pilot vaccination 
campaign animals of 571,950 head were added, the total number rose to 10,099,972 head with 
a coverage rate 79.42% of the total animal population.  The reason of low achievement rate in 
some governorates was due to the military actions in these areas during the vaccination 
campaign, which was especially noted in Ninava and Deyala where success rates were 56.18% 
and 49.57%, respectively. 
Immune Response 
       There were 267 field vaccination teams and 25% of the teams were randomly selected 
according to recommendations of several experts from Australia and USA.  Fifty blood 
samples from animals vaccinated by each team selected were collected and tested using the 
Rose Bengal Antigen test.   In five governorates that conducted the test within three to six 
weeks post-vaccination, the positive immune response rate was 82.36%.  The other 
governorates implemented the test two to three months post-vaccination, and the results 
showed a normal decline in humoral immune responses. 
 
Induced Abortion Post Vaccination 
 Abortion post-vaccination could be one of the disadvantages of using Rev-1 vaccine if it 
is used without proper timing during the gestation cycle. The total reported abortion cases post 
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vaccination were approximately 5,108 cases.  However, these abortion cases were 
accompanied by outbreaks of sheep pox and foot-and-mouth disease a month after the 
vaccination campaign, and both diseases can cause abortion in sheep and goats.  Thus, it was 
considered a very real possibility that the 5,108 could have been due to these two diseases.  
Even if it was presumed that all the abortion cases were due to the vaccination process, the 
percentage of induced abortions would be < 0.001%.  This is a very low level of abortion 
compared to the abortion cases induced in other countries, such as Tajikistan where 0.8 % of 
pregnant females aborted post-vaccination with Rev-1 vaccine administered via the 
conjunctival route.  
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Figure ‎3.2: Governorates Included in the First-Year Vaccination Program 2006 
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Table  3.2: Teams Participating in the Mass Vaccination Campaign 2006 
 
Governorate Field Support Total 
Ninava 48 3 51 
Kirkuk 17 3 20 
Baghdad 26 2 28 
Deyala 21 2 23 
Wasit 23 2 25 
Babil 16 4 20 
Kerbala 15 1 16 
Missan 17 1 18 
Thiqar 22 2 24 
Qadiseya 16 4 20 
Najaf 14 1 15 
Muthana 20 1 21 
Basra 12 3 15 
Anbar 0 0 0 
Salahadin 0 0 0 
Total 267 29 296 
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Table  3.3: Total Employees Participating in the Vaccination Campaign 2006 
 
Governorate Staff Support 
Staff 
Total 
Ninava 113 46 159 
Kirkuk 56 6 62 
Baghdad 90 0 90 
Deyala 57 28 85 
Wasit 72 31 103 
Babil 78 37 115 
Kerbala 45 9 54 
Missan 52 0 52 
Thiqar 54 33 87 
Qadiseya 52 25 77 
Najaf 44 9 53 
Muthana 33 13 46 
Basra 37 6 43 
Anbar 0 0 0 
Salahadin 0 0 0 
Total 738 243 1,626 
 
The supervisory team included 16 personnel raising the total number to 1,042 
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Table  3.4: Total Vaccinated Animals in Mass Vaccination Campaign 2006 
 
Governorate Population Vaccinated 
animals 
Achievement 
 
Ninava * 4000000 2247346 56.18 % 
Kirkuk 921000 868600 94.31 % 
Baghdad 264432 231576 87.57 % 
Deyala * 1107900 553520 49.96 % 
Wasit ** 1100000 1120596 101.87 % 
Babil ** 548900 604352 110.1 % 
Kerbala 327159 261989 80.08 % 
Missan 700000 523264 74.75 % 
Thiqar ** 600000 763257 127.21 % 
Qadiseya ** 550000 577829 105.06 % 
Najaf 560000 414236 73.97 % 
Muthana 1920000 1283822 66.87 % 
Basra 94000 77635 82.59 % 
Anbar 0 0 0 
Salahadin 0 0 0 
Total 12,693,391 9,528,022 75.06 % 
 
- Total vaccinated animals in the five southern governorates by the pilot vaccination 
campaign were 571,950 head 3-8 months of age. 
- Total vaccinated animals after two campaigns = 10,099,972 head. 
- Achievement in 13 governorates except Anbar and Salahadin was 79.42%. 
- Achievement in governorates denoted with (*) was lower than expected due to military 
actions and bad security conditions in some of the districts, incapacitating implementation 
of vaccination activities.  
- Achievement in governorates denoted with (**) was >100%, due to the enforced 
displacement of sheep flock owners from their living places where their flocks were 
officially  registered, to other more safe places because of the civil conflicts during 
implementation of the vaccination campaign.   
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Table  3.5: Immune Response after Mass Vaccination Campaign 2006 
 
Governorate Field 
teams 
Selected 
teams 
Samples + ve -ve    IR% Post Vaccinations 
Kirkuk 17 4 200 145 55 72.5 4 - 6 weeks 
Wasit 23 5 250 192 58 76.8 4 - 6 weeks 
Thiqar 22 5 250 202 48 80.8 4 - 6 weeks 
Qadiseya 16 4 200 169 31 84.5 4 - 6 weeks 
Muthana 20 5 254 247            7 97.2 3 weeks 
 
*+ve = positive, -ve=negative, IR=Immune response 
Notes: 
- Not all governorates conducted serology testing within three to six weeks post-vaccination. 
- The mean of positive immune responses in governorates that conducted the test within the 
recommended period post-vaccination was 82.36%. 
- Only Muthana governorate conducted the serology testing within three weeks post-
vaccination and the other governorates (Kirkuk, Wasit, Thiqar, and Qadiseya) conducted the 
test more than four weeks post-vaccination. 
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Second Year of the Vaccination Phase - 2007 
 
The required amount of vaccine was determined to be 4,000,000 doses, and the animals 
targeted were the new progeny of sheep and goats three to eight months of age and the adults 
missed from the previous campaign.  The goal was to return to the original plan of using a full 
dose of Rev-1 vaccine.   Unfortunately, the same problem of vaccine shortage was again 
encountered with the vaccination program because unrealistic rules and regulations were 
established to regulate the processes of vaccine importation.  The only available choice was to 
conduct a similar alternative plan as the previous year by using available vaccine (1,000,000 
doses) from the same manufacturer.  The vaccine was located in cold storage of the veterinary 
services in the Kurdistan province, where the veterinary administration had planned to vaccinate 
the target animals by using a full dose of the vaccine during the campaign in central and south 
Iraq.  The veterinary administration in Baghdad, with assistance of the US military veterinary 
service command, was able to secure only 250,000 doses of vaccine, which was enough to 
vaccinate the targeted animals after diluting the vaccine to 1x107 cfu/dose.  
There were 5 to 5.5 million head estimated to be vaccinated including the unvaccinated 
missed adults from the previous campaign in the 15 governorates except Kurdistan provinces, 
but unfortunately,  the unsafe security conditions existed for the second time in Deyala and 
Anbar  so these two governorates were not able to implement vaccination activities.  Total 
vaccinated animals were 4,698,482 head, as shown in Table 3.6. 
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Table  3.6: Total Vaccinated Animals in Vaccination Campaign 2007 
 
Governorate 
 
Vaccinated 
Animals 
Ninava * 1480407 
Kirkuk * 573619 
Baghdad 111410 
Deyala 0 
Wasit 316777 
Babil * 264031 
Kerbala 116227 
Missan 118156 
Thiqar 238563 
Kadiseya 371308 
Najaf 156545 
Muthana * 158118 
Basra 36498 
Anbar 0 
Salahadin 756823 
 
Total 
 
         4,698,482 
 
( * ) Governorates that included the missed adult animals from the previous campaign 
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Figure  3.3: Governorates Covered in Vaccination Campaign 2007 
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Third Year of Vaccination Phase - 2008 
 
The required amount of Rev-1 vaccine was not able to be imported for the third year and 
for the same reasons. Only 400,000 doses were available from the original inventory provided by 
the veterinary administration in the Kurdistan region; but there were some remaining amounts of 
vaccine in some governorates from the previous campaign.  The decision made was to continue 
the vaccination program in Ninava and Kirkuk governorates because of their large population of 
sheep and goats, and some flocks in Anbar and Deyala were also vaccinated. The targeted 
animals were lambs and kids about three to six months of age.  The full dose (2 x 109 cfu/dose) 
was used in this campaign, which was the main reason to consider this year as the weakest part 
of the vaccination phase due to the large gap created by neglecting new progeny (not enough 
vaccine).  New progeny were a significant part of the total animal population in the other 11 
governorates, and will remain as potential repository for the disease for at least 6 years among 
the vaccinated animals.  Total vaccinated animals were 578,460, 168,053, 5,140, and 1,500 head 
in Ninava, Kirkuk, Anbar, and Deyala, respectively and shown in table 3.7. 
 
Table  3.7: Vaccinated Animals in 2008 
 
Governorate Vaccinated Animals 
Ninava 578460 
Kirkuk 168053 
Anbar 5140 
Deyala 1500 
Total 753,153 
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Figure  3.4: Governorates Included in the 2008 Vaccination Campaign 
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Fourth Year of Vaccination Phase - 2009 
 Relative improvement in security conditions allowed all 15 governorates in the middle 
and south of Iraq controlled by the veterinary services in Baghdad to be involved in vaccination 
activities in 2009.  The targeted animals were only lambs and kids three to eight months old.  
Total animals vaccinated were 1,833,482 head divided into 1,696,699 lambs and 136,783 kids.  
Serological testing was implemented at the same time in all governorates within three weeks 
post-vaccination and the mean positive animals was 92.2%.  Vaccinated animal numbers are as 
shown in the Table 3.8. 
Table  3.8: Vaccinated Lambs and Kids in 2009  
 
Governorate Lambs Kids Total 
Ninava 351881 27723 379604 
Kirkuk 107682 7318 115000 
Anbar 198958 7666 206624 
Deyala 187429 29840 217269 
Salahadin * 124000 0 124000 
Baghdad 69437 6337 75774 
Wasit 149930 19283 169213 
Babil 78172 12356 90528 
Kerbala 39875 1200 41075 
Najaf 95804 3755 99559 
Qadiseya 124803 11488 136291 
Muthana 45794 4177 49971 
Missan 40519 1521 42040 
Thiqar 65106 4418 69524 
Basra * 20555 0 20555 
Total 1,696,699 136,783 1,833,482 
( *) Vaccinated animals were not categorized into lambs and kids. 
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Figure  3.5: Governorates Included in the 2009 Vaccination Campaign 
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CHAPTER 4 - DISCUSSION 
Drawbacks and Pitfalls 
 
1) Animal Identification 
Livestock in Iraq are not fully under the control of veterinary authorities because of 
social, religious and practical considerations.  In addition, methods for animal 
identification such as tagging and tattooing are difficult to use.  Screw worm infestations 
were observed during the 2005 pilot vaccination campaign in southern governorates, and 
using tattooing applicators for animal identification was a primary cause of infestations, 
which caused inconveniences for many livestock owners and some refusal to cooperate 
with veterinary authorities.  Moreover, the value of identified animals was reduced due to 
socio-religious considerations and negligence among poor farmers was another reason for 
not implementing animal identification.    
2) Flock Movement 
Generally, the husbandry system of sheep and goats in Iraq is sedentary. However, 
there is always potential seasonal movement or migration of animal flocks among 
different Iraqi governorates and also among neighboring countries. This could be 
considered one of the main causes for endemic spread of brucellosis in the country, 
which continues to hamper the veterinary authorities in controlling all diseases.  The 
present situation of open borders since the war in 2003 magnifies the problem. 
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3) Animal Census  
The livestock census should play a pivotal role in strategic planning of any national 
animal health program.  However, a census of livestock populations in Iraq has never 
been done due to various socio-economic and political situations in the country.  
Something that could be done to rectify this situation in Iraq would be to estimate the 
census according to the records of periodic vaccination campaigns.   
4) Using Different Vaccine Sources 
According‎to‎t he‎r ecommendations‎of‎the ‎“ Round‎ Table Committee on the Use of 
Rev-1 Vaccine in Small Ruminants and Cattle”‎he ld‎i n‎Alf ort, France in 1995, it was 
highly recommended to use the same vaccine during brucellosis vaccination control 
programs.    The committee recommended using vaccine from the same manufacturer 
throughout a time course that might last 10-15 years.   The main reason for consistent use 
of a particular vaccine and manufacturer would be to establish sustainable and 
homogenous immune responses.  Another important reason to use one vaccine source 
would be related to matching field strains with vaccine production strain(s).  The vaccine 
should be from a reference site that can determine residual virulence and immunogenicity 
to ensure similar levels of immunity from all batches of vaccine produced.  This issue 
was considered during the first, second, and third years of vaccination in Iraq.  
Unfortunately, in the fourth year (2009) the vaccine was changed to a different source 
with less quality, and then in 2010 the vaccine will probably be used from another 
different source.   
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5) Laboratory Capabilities 
Drastic changes in the country due to decades of wars, inappropriate policies and the 
after-effects of the 2003 war caused significant collapse in all areas of life in Iraq, 
including the veterinary activities.  Moreover, the United Nation sanction due to Security 
Council resolutions between 1990 and 2003 and beyond caused unlimited devastation on 
laboratory capabilities.  These factors played a major role in bringing down the efficiency 
of laboratory activities, which were so crucial in providing accurate data regarding 
various infectious and zoonotic diseases.   
6) Animal Health Information System 
       Animal health information systems are one of the most crucial requirements for 
successful implementation of any program.  During 2005 to 2008, there were many 
difficulties in transforming and exchanging data and information between different 
governorates.  Currently, serious and promising steps are being taken to build an accurate 
animal information system that can facilitate transferring data and urgent information 
between SCVS headquarters and veterinary services in the 15 governorates in the center 
and south of Iraq.  
7) Security Conditions. 
Unstable security conditions in the central and western parts of Iraq especially 
affected implementation of the vaccination campaigns in 2006, 2007 and 2008, which 
greatly impacted the final achievement of these campaigns.  Table 3.4 illustrates the 
achievement percentages or results of some of the unstable governorates due to military 
actions and civil conflicts.  However, there were relatively high percentages achieved in 
the stable governorates of southern Iraq.  
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8) Rules and Regulations of Vaccine Importation. 
In any disease control program there should be relevant rules and regulations which 
facilitate and support implementation of the control and eradication programs of selected 
diseases.  Major factors having a negative impact on the brucellosis control program in 
Iraq were the rules affecting importation processes of the required amounts of vaccine 
during the first four years of the vaccination program.  In addition, politics, improper 
personnel techniques and decisions by non-professionals in choosing the vaccine source 
contributed to a difficult and unstable situation in Iraq.    
 
           9) Corporation between different veterinary administrations in different regions. 
The lack of transparency and coordination between the veterinary services in both 
Baghdad and Arbil due to decades of consequences of unstable political conditions, led to 
big differences in strategies.  There should be a full discussed long term plan to control 
the disease in all 18 governorates simultaneously.  Such plan should consider all the 
related issues including the vaccine origin, route of administration, quantity that should 
cover at least 90% of the targeted animals, and periodic sero-surveillance that should be 
implemented to evaluate the efficiency of the control program.    
  10) Maintenance of official records 
Infected human cases detected in either the middle-south of Iraq or the Kurdistan 
province could not be added cumulatively because the final total number would mislead 
statistical analysis.  This was primarily due to the difference in control strategies between 
the two regions.  Accordingly, the total number of human cases in each region should be 
separate unless the two veterinary administrations established a plan to similarly manage 
all 18 governorates.    Moreover, the number of infected human cases detected by the 
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private health sector could not be added to the cases reported by official governmental 
health institutes because it would also mislead the final results.  This is due to the 
different standards and protocols implemented by various private laboratories where they 
used different diagnostic kits and techniques for obtaining serological results.  True 
incidence should be calculated according to official health documents and records. 
 
 
  
 78 
 
Outcomes 
 
After four vaccination campaigns in 2006, 2007, 2008, and 2009, even with the unacceptable 
faults, derailed steps and difficulties in some areas, several satisfactory outcomes were achieved 
in livestock productivity and human/public health:  
1) The incidence of disease according to official reported cases of the Ministry of 
Health (MOH) for the period 1988-2004 ranged between 10.6/100,000 and 27.2 
cases/100,000 people in the middle and south of Iraq.  The highest peak was 88.5 
cases/100,000 people in 1995 because it was the most stressful year of sanctions in 
Iraq as shown in Table 4.1 and Figure 4.1.  Regarding the Kurdistan province, the 
lowest incidence of the disease was 37.8 cases/100000 people in 2006 after 
conducting the vaccination campaigns in the period 1998-2005 as shown in Table 4.2 
and Figure 4.2 
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Figure  4.1: Incidence of Human Brucellosis Cases for the Period 1988-2004 
 
    After the 2003 war, there were 5347 recorded cases representing 22.7 cases/100,000 people, 
but there was a lack of appropriate recording in the middle and south of Iraq due to the 
consequences and devastating impacts of the war. 
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Table  4.1: Incidence of Human Brucellosis Cases for the Period 1988-2004 
Year 
 
Cases 
 
Population 
 
Incidence / 100000 
people 
1988 1892 17814801 10.62 
1989 2464 18349311 13.43 
1990 2819 18899860 14.92 
1991 13106 19409189 67.52 
1992 14546 19932244 72.98 
1993 14989 20469395 73.23 
1994 15476 21021022 73.62 
1995 19040 21587514 88.20 
1996 7531 22249812 33.85 
1997 8911 22932429 38.86 
1998 5305 23635988 22.44 
1999 7297 24361133 29.95 
2000 8030 25108525 31.98 
2001 8166 27748669 29.43 
2002 7189 26405133 27.23 
2003 0 27078334 0.00 
2004 4993 27768699 17.99 
                                     
 
 
 
 
 
 81 
2) According to official MOH records, there was an apparent decline in the incidence of 
brucellosis among humans in the middle and south of Iraq during the last five years 
(2005-2009).   The most recent update of 2009 revealed the incidence to be 16.99 
cases/100,000 people in the middle and south of Iraq, and 52.35 cases/100,000 people in 
the Kurdistan province, as shown in Table 4.2 and Figure 4.2. 
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        Table  4.2: Incidence of Disease in the Two Regions of Iraq 2001-2009 
 
Year Middle & South of Iraq  Kurdistan  
2001 36.45 227.19 
2002 31.29 250.88 
2003 0 151.29 
2004 20.66 64.4 
2005 21.82   40.41 
2006 16.66   37.85 
2007 13.44   66.78 
2008 16.53   61.11 
2009 16.99   52.35 
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Figure  4.2: Incidence of Brucellosis in the Two Regions of Iraq 2001-2009 
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2) According to the reports of veterinary hospitals in different governorates, more than 90% 
of affected flocks showing annual abortion cases no longer suffered from abortions in late-stage 
pregnancy after vaccination.  Moreover, there was field evidence of significant increases in 
lambing rates among vaccinated flocks. 
3) The reduced vaccine dose used during the first and second years of the vaccination 
program was useful in reducing vaccine-induced abortions post-vaccination.  
4) Because the control program yielded significant positive results, there was a beginning to 
development of new relationships between livestock owners and veterinary services.   The 
success of the control program may be considered a new epoch in Iraqi veterinary services.  The 
program also enhanced the veterinary staff working environment because they were able to 
develop and use their skills, participate in strategic planning, and receive financial support, all of 
which had been neglected for decades. 
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Summary 
 
    In Iraq, brucellosis is considered to be one of the most important zoonotic diseases, 
where it has been discovered and confirmed since 1937.  There is controversy regarding 
total livestock and small ruminant populations in Iraq because accurate census data do 
not exist.  Sheep and goats are estimated to be over 13 million head, and the other species 
such as cattle, buffalo and camels are about 2.5 million, 285,000, and 58,000 head, 
respectively.  
    Decades of unstable socio-economic and security-political conditions that were 
accompanied by the presence of the disease in livestock caused significant increases in 
human infections. There was a significant increase in disease incidence during the1990s 
due to the United Nation (UN) sanction, especially in 1995 when brucellosis reached 88.5 
cases/100,000 people according to official records of the Ministry of Health (MOH).  
Unfortunately, because of the lack in accurate reporting and monitoring processes, 
brucellosis cases that were not officially reported are estimated to be about 10-12 cases 
for each officially reported case.  Human infections in Iraq represent huge devastating 
socio-economic impacts.  
     Regarding the economic impact at the level of livestock, estimates determine the 
loss to be at least 50 billion Iraqi Dinar from only the annual abortion cases (currently $1 
= 1180 Iraqi Dinar, whereas in 1970s, one Iraqi Dinar = $3.1).  Moreover, additional 
losses come from decreased reproduction caused by temporary and permanent infertility 
of reproductive animals. 
       Veterinary authorities in Iraq established the National Project for Controlling 
Brucellosis and Tuberculosis (NPCBT) in 1995 to counter the devastating and continuous 
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effects of brucellosis.  The main objectives of the project were to design and implement 
plans for controlling the disease, and to produce the required vaccines and diagnostic kits.  
The project was established during the UN sanction when the various committees of the 
United Nation Special Commission (UNSCOM) were implementing their duties in Iraq.  
Thus, there were very limited laboratory resources, but the project was able to achieve 
several goals regarding disease control.  The project conducted several studies on Rev-1 
and S19 vaccines that protected livestock against Brucella infection in both small and 
large ruminants.  Also, more than 2.1 million doses of Rev-1 vaccine were produced in 
liquid status and more than 20,000 doses of S19 vaccine were made, as well as 
production of diagnostic kits. 
      After the war in 2003 there was a total collapse in NPCBT activities and a great 
need for rehabilitation and reorganization of the entire Veterinary Services in Iraq.  
Accordingly, there were a series of meetings with the Food and Agriculture Organization 
(FAO) experts for this purpose.  Brucellosis was considered to be one of the main 
zoonotic problems in Iraq that needed to be controlled.  The first step to control the 
disease was designing and implementing sero-surveillance to determine prevalence of the 
disease and then taking appropriate decisions regarding a control program.  It was the 
first organized national surveillance program since establishment of Veterinary Services 
in Iraq.  Surveillance revealed the apparent prevalence of brucellosis in sheep and goats 
(shoats), cattle, buffalo, and camels to be 6.51%, 1%, 1.48%, and 0.02, respectively. 
Based on the sero-surveillance outcomes, the next step was initiating the control 
phase requiring a long-term commitment to vaccination with a suitable vaccine.  Rev-1 
vaccine was determined to be the most reliable vaccine that provided protection against 
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B. melitensis, which represented the main problem in Iraq and the Middle East.  The 
vaccination program encountered several difficulties for many reasons, but ultimately and 
regardless of difficult situations, field evidence demonstrated success in the vaccination 
campaigns by reducing infected cases among vaccinated livestock and also decreased the 
incidence among humans.  The vaccination phase began with a pilot vaccination 
campaign in five southern governorates in Iraq.  The pilot was to determine strengths and 
weaknesses as a preparedness step before the mass vaccination campaign, which was 
designed to include both genders and all ages of the targeted animals.  The total 
vaccinated animals in four campaigns for the period 2006-2009 was 17,385,089 head of 
sheep and goats with different coverage rates in different governorates due to security 
conditions in some areas.  
Regardless of the difficulties and derailed steps encountered during the vaccination 
phase, there were several remarkable achievements attributed to the four vaccination 
campaigns.  The most important output was the apparent decrease in human brucellosis, 
which declined to almost 17 cases/100,000 people in the middle and south of Iraq in 2009 
compared with 27.23cases/100,000 in 2002 and 88.55 cases/100,000 in 1995.  The 
positive results revealed a crucial need to continue vaccination procedures annually in 
order to reach the lowest possible incidence rate before starting an eradication phase.   
     Based on the satisfactory outcomes of the “emergency” plan requiring dilution of 
the vaccine, we conclude the importance of the following points:  
1. Isolation, identification, and bio-typing/serotyping of bacteria. The use of proper 
bacteriological procedure to isolate and identify the bacteria plays a vital role in 
prevention of disease.  This also helps to understand the epidemiological distribution 
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and dominant serotype of bacteria prevalent in the locality, which in turn aids in 
mitigating the disease outbreak.  While considering isolation and identification 
techniques followed by biotyping or serotyping of the bacteria, reconsideration must 
be given to the infrastructure and facilities available in the unit, diagnostic 
capabilities of the unit, and ability of veterinary services to meet international 
standards.   
2. The appropriate vaccine should be selected and used in vaccination programs.  
Vaccination is a vital component of both control and prevention, and the use of 
proper vaccines is always recommended for potential control of disease.  The 
vaccine should be specific against the bacterial pathogen in question to avoid or 
lessen negative effects of the vaccine.  An example is the use of S19 vaccine in 
Mongolia to control infection caused by Brucellosis in cattle without proper 
isolation and identification of the pathogen(s) in question.  However, later isolation 
of the bacteria causing devastating effects among cattle was found to be B. 
melitensis, so a shift was made to Rev-1 vaccine after years of using S19 vaccine.  It 
is always recommended to systematically evaluate the situation by starting with 
pathogen isolation and identification, and coupled with effective sero-
epidemiological investigations for the most effective control of disease.   
3. According to Table 4.2 and Figure 4.2, it could be determined that there was 
significant importance in continuing the vaccination campaigns so there would be 
maximum coverage of targeted animals.  Such policy would play a positive role in 
improving the efficiency of the control program, and to maintain a decline in disease 
incidence.  The best example of success was the significant decline in incidence 
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observed in middle and south Iraq after the vaccination campaigns in 2006 and 
2007;  when the incidence declined from 21.82 cases/100,000 people in 2005 to 
16.66 cases/100,000 people in 2006, and then to 13.44 cases/100,000 people in 
2007.  However, the incidence began to increase to 16.53 cases and 16.99 
cases/100,000 people in 2008 and 2009, respectively due to several factors.  One of 
the factors was the limited amount of available vaccine in 2008 which was only 
400,000 doses used as full dose.  Consideration should have been given to the 
importance of conducting vaccination protocols which were consistent with those 
implemented in 2006 and 2007, to maximize the amount of vaccine coverage of 
targeted animals.  In the Kurdistan province, the positive results of the vaccination 
campaigns in the periods 1988-2005, showed a decline in incidence to 37.85 
cases/100000 people in 2006.  However, it increased again in 2007, 2008, and 2009 
in when it reached 52.35 cases/100000 people due to the lack of continuing the 
vaccination processes.  These facts reflect the crucial needs for a unique, long-term 
vaccination program that would cover the entire 18 governorates at the same time 
and for not less than 10-15 years.           
4. Utilization of proper dosages of vaccine during vaccination campaigns is very 
important. Using a reduced dose of vaccine during the first year (2006) of the 
vaccination control program was much safer than using the full dose because it 
overcame the risk of abortion post-vaccination and mitigated potential shed of 
organisms in milking animals (dilution scheme shown in Appendix A). The result 
was similar to the outcome of a brucellosis control program implemented in Saudi 
Arabia during the 1990s when the reduced-dose vaccine at 1x106 cfu/dose was used 
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to vaccinate animals over eight months of age.   There are other important reasons 
that justify implementing a policy of using reduced doses of Rev-1 vaccine.   A key 
reason may be related to limited resources, such as a shortage in budgets available to 
acquire the needed vaccine.  Many of the developing and under developed countries 
including countries with limited resources and or budget could utilize these 
vaccination techniques and dose adjustment protocols to meet their needs for 
effective implementation and control of the disease.  The vaccine provided five 
years of immune protection among animals. 
5. Implementation of surveillance programs is critical. It is important to develop an 
Animal Health Information System (AHIS) for creating geo-reference maps that 
reveal the actual status of all infectious diseases.  Such a system would play a major 
role in providing decision makers with accurate inputs regarding several issues 
related to livestock management, including movement control during disease 
outbreaks, nomadic movement or migration and animals smuggling across the 
borders.  A system could be considered an instrumental tool to manage other 
infectious and transboundary diseases.  This could be achieved by implementing a 
well-designed project for monitoring the movement of animal flocks within the 
country or across the borders by using the GIS and remote sensing technologies.  To 
measure the progress of the control program, a coordinated surveillance program 
should be developed.  Such a program is so important to facilitate monitoring and 
follow-up processes necessary to determine the prevalence of the disease among 
livestock. 
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6. Training programs to increase awareness about the disease would be valuable.  
Continuous training programs for all staff of the Veterinary Services would develop 
and increase their capabilities in performing different veterinary activities whether in 
the field or in laboratories.  Developing laboratory and field skills can enhance the 
accuracy of the data provided from those activities.  
7. Training programs targeting livestock owners should be conducted to educate them 
about the significant zoonotic potential of brucellosis and also to increase 
knowledge of the vaccination campaign, which would facilitate owner and 
veterinary staff relationships for effective control of disease.  Since the vast majority 
of livestock owners are of limited educational level, there is great need for 
continuous education and awareness programs.  The programs would enhance and 
develop cooperation with veterinary authorities that would lead to higher levels of 
achievement during vaccination and surveillance programs. 
8. Establishing a nationwide (Iraq) network that joins all related ministries to enhance 
cooperation and coordination regarding related issues, and to overcome the 
difficulties that might be encountered during implementation of annual vaccination 
campaigns.  In addition, it is also crucial to follow-up the disease incidence among 
humans, which reflects the accuracy of the whole control program.  The program 
related issues must be properly planned for implementation within actual time 
frames and provide the required capacities as brucellosis is considered as a 
national/regional priority.  Thus, high level organization and cooperation between all 
related stakeholders would be crucial. 
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9. Regional control of the disease is needed.  Since brucellosis is one of the serious 
trans-boundary diseases, there is a crucial need for more cooperation between 
neighboring countries in the Middle East region.  A regional control program for 
disease control is imperative and would require transparency in reporting and 
exchanging information, including humans and domestic animals. 
10. Laws and regulations for disease control should be updated and harmonized with 
international standards. The national laws and regulations have essentially remained 
since 1936-1937.  Legislation should be initiated that would create regulations 
consistent with what is known about the disease (organism, epidemiology), the 
needs and expectations of stakeholder in the country and the rest of the world, and 
the requirements for eradication of brucellosis. New laws and regulations also 
should take into consideration how programs will be implemented at the local level.  
Compensation to livestock owners for animals lost due to the program should be 
considered as well.  Finally, implementation of uniform, nationwide regulatory 
policies are critical for an effective disease eradication program.  
11. Effective eradication of any disease requires cooperation and transparency in 
exchanging information among all relevant stakeholders, and Veterinary Services in 
Iraq should be pivotal in that regard, which would increase the Program coverage 
and data collection of data from all 18 governorates would be enhanced by 
utilization of Veterinary Services staff that is fully engaged and properly supported.  
Transparency among stakeholders would be essential for the most effective 
reporting and information exchange among and species, including humans and 
domestic animals.   
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Appendix A - Vaccine dilution procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal Saline 
100 ml Vaccine 
25 doses 
2X10
9
 /dose 
Vaccine  
25 doses 
 
     
     Normal Saline  
99 ml 
Step 1  
Step 2 
Step 3 
Re-suspension of lyophilized 
vaccine with diluent by using 
disposable syringe.  
Bring a bottle of 100ml of 
8.5% Normal Saline. 
Discard 1ml of Normal 
Saline by using the 
disposable syringe. 
1 ml out 
Vaccine 
25 doses 
2X10
9
 /dose 
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Appendix A- Continue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
       
     Normal Saline  
           99 ml 
Vaccine 
25 doses   
2X10
9
 /dose 
  1ml Vaccine  Step 
Step 5 
Vaccine 
          100 doses 
         2X10
7
 /dose 
 
Vaccine 
24 doses 
2X10
9
 /dose 
Take 1ml of vaccine 
by disposal syringe   
Add 1ml of concentrated 
vaccine to 99 ml of 
Normal Saline.  
Bottle of the final dilution 
contains 100 doses with 
concentration 2 x 10
7
/dose 
which can be used for 
vaccinating 100 heads. 
Vial of concentrated vaccine with 
24 doses remaining in it with 
concentration 2 x 10
9
/dose, which 
can be used for another 24 
dilution processes. 
